What alternative medications can be used instead of Myrbetriq (mirabegron) for overactive bladder?

Alternative Medications to Myrbetriq for Overactive Bladder

For patients who cannot take Myrbetriq (mirabegron), antimuscarinic medications—specifically tolterodine extended-release or solifenacin—are the recommended alternatives, with tolterodine showing the lowest risk of treatment discontinuation due to adverse effects among antimuscarinics. 1

First-Line Treatment: Behavioral Therapies (Mandatory Before or With Medication)

Before prescribing any pharmacologic alternative, all patients must begin structured behavioral interventions including bladder training, pelvic floor muscle training, and fluid management for 8–12 weeks, as these approaches achieve symptom reduction comparable to antimuscarinic drugs with no adverse effects. 1, 2

• Weight loss and exercise should be recommended for obese patients, as this can reduce incontinence episodes by up to 47%. 2
• Behavioral therapies should continue even after starting medication to maintain optimal symptom control. 2

Second-Line Pharmacologic Alternatives to Mirabegron

Preferred Antimuscarinic Options

Tolterodine extended-release (4 mg once daily) is the preferred first antimuscarinic alternative because it demonstrates discontinuation rates due to adverse effects similar to placebo and offers better tolerability than immediate-release formulations. 1, 2

Solifenacin (5 mg once daily) is another excellent option, particularly if combination therapy with mirabegron becomes necessary later, as this specific combination has the strongest evidence base. 2, 3

Darifenacin is recommended for patients with cognitive concerns, as this selective M3 receptor antagonist has a lower risk of cognitive effects and discontinuation rates similar to placebo. 1, 2

Comparative Safety Profile Among Antimuscarinics

• Solifenacin has the lowest risk for discontinuation due to adverse effects among all antimuscarinics (NNTH 78), while oxybutynin has the highest risk (NNTH 16). 1
• Only darifenacin and tolterodine show discontinuation rates statistically similar to placebo. 1
• Fesoterodine, while effective, has higher discontinuation rates (NNTH 33) compared to tolterodine. 1

Special Population Considerations

Elderly and Cognitively Impaired Patients

In elderly patients or those with cognitive concerns, avoid antimuscarinics if possible due to cumulative, dose-dependent dementia risk. 2 If mirabegron is contraindicated and an antimuscarinic must be used:

• Choose darifenacin first due to its selective M3 receptor antagonism and lower cognitive risk. 2
• Tolterodine extended-release is the second choice in this population. 2
• Frail patients (those with mobility deficits, unexplained weight loss, weakness, or existing cognitive deficits) require extreme caution with all OAB medications due to a lower therapeutic index. 2

Patients with Specific Contraindications

Screen all patients before prescribing antimuscarinics for absolute contraindications: narrow-angle glaucoma, impaired gastric emptying, and history of urinary retention. 2

• In patients with narrow-angle glaucoma, impaired gastric emptying, or urinary retention history, antimuscarinics are contraindicated; mirabegron would be the safer choice, but if mirabegron is also unavailable, third-line options (neuromodulation, botulinum toxin) should be considered. 2, 4

Patients with Renal or Hepatic Impairment

For antimuscarinic alternatives in patients with organ dysfunction, dose adjustments may be necessary—consult specific drug labeling for each agent. 4

Treatment Algorithm When Mirabegron Is Not an Option

1. Initiate or optimize behavioral therapies (bladder training, pelvic floor exercises, fluid management). 2

2. Select an initial antimuscarinic based on patient profile:

   • Cognitive concerns or elderly: darifenacin or tolterodine ER 2
   • General population: tolterodine ER 4 mg or solifenacin 5 mg 2
   • Avoid oxybutynin due to highest discontinuation rates 1

3. Trial the medication for 4–8 weeks to assess efficacy and tolerability. 2

4. If first antimuscarinic fails or causes intolerable side effects, switch to a different antimuscarinic agent rather than abandoning the class entirely—many patients achieve better symptom control or tolerability with different agents. 2

5. If multiple antimuscarinics fail, consider third-line options: intradetrusor onabotulinumtoxinA injections, sacral neuromodulation, or peripheral tibial nerve stimulation. 2

Managing Adverse Effects

Dry mouth is the most frequent complaint with antimuscarinic agents (occurring in 2.3–8.6% depending on agent), with oxybutynin having the highest rate (8.6%) and mirabegron the lowest (2.3–2.8%). 1

Constipation should be monitored and managed proactively, as it is a common adverse effect of all antimuscarinics. 1, 2

If adverse effects limit tolerability, first attempt dose reduction or add intensified behavioral techniques (prompted voiding, individualized fluid management) before discontinuing the medication. 2

Common Pitfalls to Avoid

• Do not abandon antimuscarinic therapy after failure of one medication without trying another agent—evidence supports the benefit of switching within the class. 2
• Do not prescribe antimuscarinics to patients with narrow-angle glaucoma, impaired gastric emptying, or history of urinary retention without confirming absence of these contraindications. 2, 4
• Do not fail to optimize behavioral therapies before starting medications—this is the most common error in OAB management. 2
• Do not overlook cognitive risks when prescribing antimuscarinics, especially in elderly patients—consider darifenacin or avoid the class if possible. 2

Newer β3-Agonist Alternative

Vibegron is a newer β3-adrenergic agonist that may be more effective than mirabegron in relieving urgency urinary incontinence in female patients, with similar safety profiles. 5 If mirabegron is unavailable due to supply issues rather than contraindications, vibegron represents an equivalent alternative within the same drug class. 6, 5